



FOR IMMEDIATE RELEASE

CONTACT: Mark Holman, CEO
TELEPHONE: (530) 298-7201 ext. 707
EMAIL: mark.holman@expanesthetics.com
WEBSITE: www.expanesthetics.com/media
ADDRESS: 1260 Lake Blvd Ste 231, Davis, California, 95616, USA

EXPANESTHETICS RAISES ADDITIONAL \$1.1 MILLION

Davis, California (August 14, 2018) – Northern California pharmaceutical company Expanesthetics announces more than one million dollars in additional funding from existing shareholders. The funding will be used to continue to advance the company’s R&D initiatives and strengthen the company’s growing global collaborations. Expanesthetics is the global leader in the search for improved inhaled surgical anesthetics.

“These funds energize our work to develop new inhalation general anesthetics and non-opioid analgesics,” said CEO Mark Holman. Expanesthetics is searching for new general anesthetic drugs to be used in surgery and new pain medicines.

“We are pleased that our investors, over half of whom are anesthesiologists and other clinicians, continue to show their confidence in our programs through renewed investment,” said Chief Operating Officer Shane Austin. Senior VP Landon Ellis remarked about the investment, “Expanesthetics was named a finalist in the Buzz of BIO competition at the global biotechnology conference held in June in Boston. There we presented to a global audience about the potential impact of our development on unmet medical needs, high healthcare costs, and increased patient comfort. This investment allows us to move forward toward those goals.”

The terms of the offering were not disclosed.

- MORE -

1260 Lake Blvd Ste 231
Davis, CA 95616
www.expanesthetics.com



FOR IMMEDIATE RELEASE

August 14, 2018

Page 2

ABOUT EXPANESTHETICS: Based on new scientific discoveries and inventions it has licensed exclusively on a worldwide basis, Davis, California-based Expanesthetics, Inc. is working to expand the choice of inhaled general anesthetics available to anesthesia professionals in order to improve patient outcomes and simultaneously reduce the overall cost of anesthetic delivery. It is also developing non-opioid analgesics.

###